ASP2905
Selective Kv12.2 (KCNH3) potassium channel inhibitor, attention-enhancing candidate, preclinical data only.
Pharmacology
Contents
WHAT IS ASP2905?
Detailed overview
ASP2905 is an experimental compound developed by Astellas that acts as a potent and selective inhibitor of the Kv12.2 (KCNH3-encoded) voltage-gated potassium channel. This channel is concentrated in the forebrain: its overexpression produces cognitive deficits in rodents, whereas its knockout improves attention and learning, so blocking the channel increases excitatory neuronal activity in cognitive circuits. In mouse models ASP2905 reversed memory deficits induced by MK-801 and scopolamine, improved learning in aged rats, and showed antipsychotic-like activity as well as attention-enhancing effects in an ADHD model; in rat microdialysis it increased dopamine and acetylcholine efflux in the medial prefrontal cortex. There is no human clinical data: efficacy and safety in humans are unstudied and the compound exists only as a preclinical research chemical.
Mechanism
Kv12.2 (KCNH3) potassium channel inhibition
Evidence
Preclinical only (no human data)
Legal status
Unapproved research chemical
Receptor profile
- Kv12.2 / KCNH3 potassium channelStrong
- Prefrontal dopamine efflux (indirect)Moderate
- Prefrontal acetylcholine efflux (indirect)Moderate
Safety
Side effects, stop signs, contraindications
Side effects · 5
- No human safety data: only preclinical (mouse and rat) studies exist; the compound has never been tested in humans
- Increased neuronal excitability may theoretically cause restlessness, anxiety or sleep disturbance
- A psychoactive (behavior-altering) effect was demonstrated in mice, indicating dose-dependent behavioral change
- Theoretical seizure risk, since Kv12.2 inhibition raises excitatory neuronal activity in the forebrain
- Unknown long-term safety and missing toxicity profile in humans
Contraindications · 4
- Pregnancy and breastfeeding: safety not established, avoid
- Epilepsy or lowered seizure threshold: increased forebrain excitability may theoretically raise seizure risk
- Avoid combining with other stimulant / dopaminergic agents due to additive overstimulation
- Not an approved medicine; experimental research chemical, not recommended without clinical supervision
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
ASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the Kcnh3 gene, is psychoactive in mice
Takahashi S, Okamura A, Yamazaki M, Ni K
The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder
Takahashi S, Ohmiya M, Honda S, Ni K
FAQ
FAQ
Selective Kv12.2 (KCNH3) potassium channel inhibitor, attention-enhancing candidate, preclinical data only.
Telegram
Have a question about ASP2905?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.